NUVL
Nuvalent, Inc.Company Information
- Company Name
- Nuvalent, Inc.
- CIK
- CIK0001861560
- Category
- Large accelerated filer
- Ticker: Exchange
- NUVL: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- NUVL
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-07-09
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 1,458,181
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 73,369,895
- Shares outstanding
- 78,670,371
- Ownership
- 93.26%
Earnings Market Reaction
- Filing date
- 2026-05-07
- Price on filing date
- —
- 1-month reaction
- 7.80%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 160 | 262 | 116 | 127 | 121 | 146 | 369 | 78 | 99 | 335 | 88 | 71 | ||||||
| Marketable Securities Current | 1,128 | 1,110 | 827 | 878 | 952 | 973 | 799 | 580 | 593 | 385 | 325 | 360 | ||||||
| Prepaid Expense And Other Assets Current | 20 | 20 | 14 | 14 | 13 | 14 | 11 | 8 | 8 | 7 | 7 | 6 | ||||||
| Assets Current | 1,308 | 1,392 | 957 | 1,020 | 1,087 | 1,132 | 1,180 | 666 | 699 | 726 | 420 | 437 | ||||||
| Other Assets Noncurrent | 23 | 20 | 23 | 21 | 19 | 9 | 9 | 9 | 9 | 6 | 5 | 5 | ||||||
| Assets | 1,331 | 1,413 | 980 | 1,041 | 1,106 | 1,142 | 1,189 | 675 | 708 | 732 | 425 | 442 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 22 | 30 | 22 | 13 | 26 | 5 | 16 | 7 | 13 | 9 | 10 | 8 | ||||||
| Accrued Liabilities And Other Liabilities | 59 | 61 | 67 | 62 | 49 | 49 | - | - | - | - | - | - | ||||||
| Accrued Liabilities Current | - | - | - | - | - | 49 | 35 | 31 | 20 | 23 | 19 | 13 | ||||||
| Liabilities Current | 81 | 91 | 89 | 75 | 75 | 54 | 51 | 38 | 33 | 32 | 29 | 21 | ||||||
| Other Liabilities Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | ||||||
| Liabilities | 157 | 164 | 135 | 101 | 95 | 72 | 68 | 38 | 33 | 32 | 29 | 21 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 2,257 | 2,218 | 1,697 | 1,670 | 1,642 | 1,617 | 1,592 | 1,027 | 1,007 | 987 | 645 | 637 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | 2 | 2 | 1 | 1 | -0 | 1 | -2 | -1 | 0 | -1 | -2 | ||||||
| Retained Earnings Accumulated Deficit | -1,082 | -972 | -854 | -731 | -632 | -547 | -472 | -388 | -331 | -286 | -248 | -214 | ||||||
| Stockholders Equity | 1,174 | 1,248 | 845 | 940 | 1,011 | 1,070 | 1,121 | 637 | 675 | 701 | 396 | 421 | ||||||
| Liabilities And Stockholders Equity | 1,331 | 1,413 | 980 | 1,041 | 1,106 | 1,142 | 1,189 | 675 | 708 | 732 | 425 | 442 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialNuvalent, Inc. (NUVL) — SEC Financial Statements & Analysis
Nuvalent, Inc. (NUVL) is a pharmaceutical preparations company, incorporated in DE. Nuvalent, Inc. trades on Nasdaq as: NUVL. Nuvalent, Inc. (NUVL)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-05-07. Based on that filing, On profitability, Nuvalent, Inc. posts a Return on Equity (ROE) of -41.19%, a Return on Assets (ROA) of -36.94%, and a Return on Invested Capital (ROIC) of -46.08%. Per share, it reports EPS of $-5.72, diluted EPS of $-5.72, free cash flow per share of $-3.98, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 49.60% year-over-year and EPS growth of 36.17% year-over-year. On the balance sheet, it maintains a current ratio of 16.14x, a quick ratio of 15.88x, working capital of $1.23B, a debt-to-equity ratio of 0.13x, a debt ratio of 0.12, free cash flow of $-312.79M (TTM), and net debt of $-159.73M. Figures sourced from SEC EDGAR.
- EPS TTM
- $-5.72
- ROE TTM
- -41.19%
- ROA TTM
- -36.94%
- Debt To Equity
- 0.13x
- Free Cash Flow TTM
- $-312.79M
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Nuvalent, Inc. in?
Nuvalent, Inc. (NUVL) operates in the Pharmaceutical Preparations industry.
What exchange does NUVL trade on?
Nuvalent, Inc. (NUVL) trades on the Nasdaq.
Where is Nuvalent, Inc. incorporated?
Nuvalent, Inc. is incorporated in DE.
When was Nuvalent, Inc. (NUVL)'s most recent SEC filing?
Nuvalent, Inc. (NUVL)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-05-07.
What is NUVL's EPS (earnings per share)?
Nuvalent, Inc. (NUVL)'s trailing twelve month EPS is $-5.72 as of 2026-03-31.
What is NUVL's ROE (return on equity)?
Nuvalent, Inc. (NUVL)'s trailing twelve month Return on Equity (ROE) is -41.19% as of 2026-03-31.
What is NUVL's ROA (return on assets)?
Nuvalent, Inc. (NUVL)'s trailing twelve month Return on Assets (ROA) is -36.94% as of 2026-03-31.
What is NUVL's ROIC (return on invested capital)?
Nuvalent, Inc. (NUVL)'s trailing twelve month Return on Invested Capital (ROIC) is -46.08% as of 2026-03-31.